Neuroprotective therapies in the NICU in preterm infants: present and future (Neonatal Neurocritical Care Series)

Eleanor J. Molloy*, Mohamed El-Dib, Janet Soul, Sandra Juul, Alistair J. Gunn, Karen Luyt, et al

*Corresponding author for this work

Research output: Contribution to journalReview article (Academic Journal)peer-review

Abstract

The survival of preterm infants has steadily improved thanks to advances in perinatal and neonatal intensive clinical care. The focus is now on finding ways to improve morbidities, especially neurological outcomes. Although antenatal steroids and magnesium for preterm infants have become routine therapies, studies have mainly demonstrated short-term benefits for antenatal steroid therapy but limited evidence for impact on long-term neurodevelopmental outcomes. Further advances in neuroprotective and neurorestorative therapies, improved neuromonitoring modalities to optimize recruitment in trials, and improved biomarkers to assess the response to treatment are essential. Among the most promising agents, multipotential stem cells, immunomodulation, and anti-inflammatory therapies can improve neural outcomes in preclinical studies and are the subject of considerable ongoing research. In the meantime, bundles of care protecting and nurturing the brain in the neonatal intensive care unit and beyond should be widely implemented in an effort to limit injury and promote neuroplasticity.
Original languageEnglish
JournalPediatric Research
Early online date19 Dec 2023
DOIs
Publication statusE-pub ahead of print - 19 Dec 2023

Fingerprint

Dive into the research topics of 'Neuroprotective therapies in the NICU in preterm infants: present and future (Neonatal Neurocritical Care Series)'. Together they form a unique fingerprint.

Cite this